SCHEMBL30217822

SCHEMBL30217822

COCCOc1cc2c(N3CCN(C(=O)OC(C)(C)C)CC3)ccc(Br)c2nn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 0.42
RET P07949 1/20 0.41
GPR119 Q8TDV5 3/20 0.41
LMNA P02545 1/20 0.41
SMARCA2 P51531 1/20 0.40
SMARCA4 P51532 1/20 0.40
PBRM1 Q86U86 1/20 0.40
KCNH2 Q12809 2/20 0.40
MAP4K4 O95819 1/20 0.39
KIT P10721 1/20 0.38
POLB P06746 1/20 0.38
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
DTYMK P23919 1/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25096369 1.00 BACE1 (0.42) BACE1RETGPR119LMNASMARCA2
SCHEMBL25097076 0.89 GPR119 (0.42) BACE1RETGPR119SMARCA2SMARCA4
SCHEMBL30217579 0.89 GPR119 (0.42) BACE1RETGPR119SMARCA2SMARCA4
SCHEMBL25096995 0.88 SMARCA2 (0.44) BACE1GPR119LMNASMARCA2SMARCA4
SCHEMBL30217836 0.88 BACE1 (0.40) BACE1RETGPR119LMNASMARCA2
SCHEMBL25096370 0.88 BACE1 (0.40) BACE1RETGPR119LMNASMARCA2
SCHEMBL28939509 0.81 LMNA (0.46) BACE1RETGPR119LMNASMARCA2
SCHEMBL25096871 0.81 KCNH2 (0.44) BACE1GPR119LMNASMARCA2SMARCA4
SCHEMBL30217729 0.81 KCNH2 (0.44) BACE1GPR119LMNASMARCA2SMARCA4
SCHEMBL25096367 0.81 BACE1 (0.46) BACE1RETGPR119LMNASMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2024-12-12 US disclosed
EP-4395891-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 EP disclosed
WO-2023034811-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 BACE1 668/4885RET 4144/4885GPR119 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.